Jamshedpur Reporter

Community-Acquired Bacterial Pneumonia Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2022-2032), States DelveInsight | Key Companies – Nabriva Therapeutics, Melinta

 Breaking News
  • No posts were found

Community-Acquired Bacterial Pneumonia Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2022-2032), States DelveInsight | Key Companies – Nabriva Therapeutics, Melinta

March 24
00:15 2023
Community-Acquired Bacterial Pneumonia Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2022-2032), States DelveInsight | Key Companies - Nabriva Therapeutics, Melinta
The Community-Acquired Bacterial Pneumonia market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Community-Acquired Bacterial Pneumonia pipeline products will significantly revolutionize the Community-Acquired Bacterial Pneumonia market dynamics.

DelveInsight’s “Community-Acquired Bacterial Pneumonia Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Community-Acquired Bacterial Pneumonia, historical and forecasted epidemiology as well as the Community-Acquired Bacterial Pneumonia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

The Community-Acquired Bacterial Pneumonia market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

 

To Know in detail about the Community-Acquired Bacterial Pneumonia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Community-Acquired Bacterial Pneumonia Market Insights

 

Community-Acquired Bacterial Pneumonia Overview

Community-Acquired Bacterial Pneumonia pneumonia (CABP) is a common, acute, severe infection of the lung parenchyma. It is a major cause of mortality in adults. It is one of the most frequent respiratory illnesses among various infections triggering sepsis. The Global Burden of Disease Study identified lower respiratory tract infection (LRTI) as the second most common cause of death and years of life lost. Microbiologically, bacteria are common agents in pneumonia, with Streptococcus pneumoniae being the most common cause worldwide.

 

Some of the key facts of the Community-Acquired Bacterial Pneumonia Market Report: 

  • The Community-Acquired Bacterial Pneumonia market size was valued approximately USD 2600 Million in the year 2022 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • The total incident cases of Community-Acquired Bacterial Pneumonia Pneumonia (CABP) were 6,936,578 cases in the 7MM in 2021, which is expected to increase by 2032
  • Among the EU4 countries and the United Kingdom, Germany has the highest number of incident cases of Community Acquired Bacterial Pneumonia (CABP), which were 566,045 cases in 2019. As per DelveInsight’s analysis this is expected to increase by 2032
  • Community-acquired pneumonia is a leading cause of hospitalization, mortality, and incurs significant health care costs. According to Sattar & Sharma, 2021, the estimated worldwide incidence of community-acquired pneumonia varies between 1.5 to 14 cases per 1000 person-years, and this is affected by geography, season, and population characteristics
  • As per population based studies conducted by The ilacker et al 2021, CAP incidence in German adults remain high with an overall rate of 1,054 per 100,000 person-years of observation
  • In the UK based on NICE estimates; every year between 0.5% and 1% of adults have community-acquired pneumonia
  • Key Community-Acquired Bacterial Pneumonia Companies: Nabriva Therapeutics, Melinta Therapeutics, Wakunaga Pharmaceutical, Forest Pharmaceuticals, Pfizer, Paratek Pharmaceuticals, Cumberland Pharmaceuticals Inc., Theravance Biopharma, Merck Sharp & Dohme Inc., Cubist Pharmaceuticals LLC, Shionogi Inc., Allergan, Eagle Pharmaceutical Inc, Combioxin SA, Takeda, TiGenix, AstraZeneca, Chia Tai Tianqing Pharmaceuticals, Clarametyx Biosciences, Inc., Pfizer, and others
  • Key Community-Acquired Bacterial Pneumonia Therapies: CAL02, Cx611, Ceftaroline, Ceftriaxone, Levofloxacin, Delafloxacin, amoxicillin clavulanate, Omadacycline, Faropenem, Lefamulin, CMTX-101, Tigecycline, and others

 

Get a Free sample for the Community-Acquired Bacterial Pneumonia Market Report – 

https://www.delveinsight.com/sample-request/community-acquired-bacterial-pneumonia-cabp-market

 

Key benefits of the Community-Acquired Bacterial Pneumonia Market report:

  1. Community-Acquired Bacterial Pneumonia market report covers a descriptive overview and comprehensive insight of the Community-Acquired Bacterial Pneumonia Epidemiology and Community-Acquired Bacterial Pneumonia market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
  2. The Community-Acquired Bacterial Pneumonia market report provides insights on the current and emerging therapies.
  3. Community-Acquired Bacterial Pneumonia market report provides a global historical and forecasted market covering drug outreach in 7MM.
  4. The Community-Acquired Bacterial Pneumonia market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Community-Acquired Bacterial Pneumonia market.

 

Download the report to understand which factors are driving Community-Acquired Bacterial Pneumonia epidemiology trends @ Community-Acquired Bacterial Pneumonia Epidemiological Insights

 

Community-Acquired Bacterial Pneumonia Market  

The dynamics of the Community-Acquired Bacterial Pneumonia market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032. 

 

 

Community-Acquired Bacterial Pneumonia Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Community-Acquired Bacterial Pneumonia Epidemiology Segmentation:

The Community-Acquired Bacterial Pneumonia market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Community-Acquired Bacterial Pneumonia
  • Prevalent Cases of Community-Acquired Bacterial Pneumonia by severity
  • Gender-specific Prevalence of Community-Acquired Bacterial Pneumonia
  • Diagnosed Cases of Episodic and Chronic Community-Acquired Bacterial Pneumonia

 

Community-Acquired Bacterial Pneumonia Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Community-Acquired Bacterial Pneumonia market or expected to get launched during the study period. The analysis covers Community-Acquired Bacterial Pneumonia market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Community-Acquired Bacterial Pneumonia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Discover more about therapies set to grab major Community-Acquired Bacterial Pneumonia market share @ Community-Acquired Bacterial Pneumonia market forecast

 

Community-Acquired Bacterial Pneumonia Therapies and Key Companies

  • CAL02: Eagle Pharmaceuticals Inc.
  • Cx611: Takeda/TiGenix
  • Ceftaroline: Pfizer
  • Ceftriaxone: Forest Laboratories
  • Levofloxacin: Melinta Therapeutics, Inc.
  • Delafloxacin: Melinta Therapeutics, Inc.
  • amoxicillin clavulanate: AstraZeneca
  • Omadacycline: Paratek Pharmaceuticals Inc
  • Faropenem: Chia Tai Tianqing Pharmaceuticals
  • Lefamulin: Nabriva Therapeutics AG
  • CMTX-101: Clarametyx Biosciences, Inc.
  • Tigecycline: Pfizer

 

Community-Acquired Bacterial Pneumonia Market Strengths

  • Increasing prevalence of specific risk factors for CABP has fuelled substantial economic and clinical burden of the infections worldwide, with a host of treatment modalities to manage CABP thereby, fulfilling the growth of the market, especially in developed nations

 

Scope of the Community-Acquired Bacterial Pneumonia Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Community-Acquired Bacterial Pneumonia Companies: Nabriva Therapeutics, Melinta Therapeutics, Wakunaga Pharmaceutical, Forest Pharmaceuticals, Pfizer, Paratek Pharmaceuticals, Cumberland Pharmaceuticals Inc., Theravance Biopharma, Merck Sharp & Dohme Inc., Cubist Pharmaceuticals LLC, Shionogi Inc., Allergan, Eagle Pharmaceutical Inc, Combioxin SA, Takeda, TiGenix, AstraZeneca, Chia Tai Tianqing Pharmaceuticals, Clarametyx Biosciences, Inc., Pfizer, and others
  • Key Community-Acquired Bacterial Pneumonia Therapies: CAL02, Cx611, Ceftaroline, Ceftriaxone, Levofloxacin, Delafloxacin, amoxicillin clavulanate, Omadacycline, Faropenem, Lefamulin, CMTX-101, Tigecycline, and others
  • Community-Acquired Bacterial Pneumonia Therapeutic Assessment: Community-Acquired Bacterial Pneumonia current marketed and Community-Acquired Bacterial Pneumonia emerging therapies
  • Community-Acquired Bacterial Pneumonia Market Dynamics: Community-Acquired Bacterial Pneumonia market drivers and Community-Acquired Bacterial Pneumonia market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Community-Acquired Bacterial Pneumonia Unmet Needs, KOL’s views, Analyst’s views, Community-Acquired Bacterial Pneumonia Market Access and Reimbursement 

 

Community-Acquired Bacterial Pneumonia Market Opportunities

  • The incidence of CABP will undoubtedly increase in the next decade due to ageing population and subsequent increase in the next decade due to ageing population and subsequent increase in comorbidities. The study of resistance to existing antibiotic treatment modalities for CABP will define new therapeutic strategies that will facilitate the CABP market

 

Table of Contents 

1. Community-Acquired Bacterial Pneumonia Market Report Introduction

2. Executive Summary for Community-Acquired Bacterial Pneumonia

3. SWOT analysis of Community-Acquired Bacterial Pneumonia

4. Community-Acquired Bacterial Pneumonia Patient Share (%) Overview at a Glance

5. Community-Acquired Bacterial Pneumonia Market Overview at a Glance

6. Community-Acquired Bacterial Pneumonia Disease Background and Overview

7. Community-Acquired Bacterial Pneumonia Epidemiology and Patient Population

8. Country-Specific Patient Population of Community-Acquired Bacterial Pneumonia 

9. Community-Acquired Bacterial Pneumonia Current Treatment and Medical Practices

10. Community-Acquired Bacterial Pneumonia Unmet Needs

11. Community-Acquired Bacterial Pneumonia Emerging Therapies

12. Community-Acquired Bacterial Pneumonia Market Outlook

13. Country-Wise Community-Acquired Bacterial Pneumonia Market Analysis (2019–2032)

14. Community-Acquired Bacterial Pneumonia Market Access and Reimbursement of Therapies

15. Community-Acquired Bacterial Pneumonia Market Drivers

16. Community-Acquired Bacterial Pneumonia Market Barriers

17.  Community-Acquired Bacterial Pneumonia Appendix

18. Community-Acquired Bacterial Pneumonia Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

To know more about Community-Acquired Bacterial Pneumonia treatment, visit @ Community-Acquired Bacterial Pneumonia Medications

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting

Recent Posts

Advanced Melanoma Pipeline Outlook Report 2024 | Clinical Trials, FDA, EMA, PMDA Approvals, Drugs and Companies

Read Full Article

Categories